Plus   Neg

Lipocine Inc. (LPCN) Is Sinking After FDA Votes Against TLANDO

Lipocine Inc. (LPCN) announced after the close Wednesday that its New Drug Application for its oral testosterone product candidate TLANDO has failed to win support from an advisory committee to FDA.

Lipocine has gapped open sharply lower Thursday morning and is now down 1.73 at $1.73 on above average volume. The stock has plunged to a new low for the year.

For comments and feedback contact: editorial@rttnews.com

Business News

$5 And Under

0 Articles
Follow RTT